Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An open label phase II trial. https://hovon.nl/nl/trials/ho164-patient